In our screen, a large fraction of lymphoma, breast and multiple myeloma cell lines exhibited close to complete growth inhibition or a net cell death phenotype, suggesting that these tumour types are the most vulnerable to the attenuation of PRMT5 activity in vitro. This evidence concerns the gene PRMT5 and plasma cell myeloma.